Brain Organoid Culture: From Neural Induction to Maturation

1. Introduction to Brain Organoid Technology

The human brain is the most complex organ in the body, comprising approximately 86 billion neurons and an even larger number of glial cells organized into highly specialized regions with distinct cytoarchitecture, connectivity patterns, and functional specializations. Understanding human brain development, neurodevelopmental disorders, and neurodegenerative diseases has been severely limited by the lack of physiologically relevant in vitro models. Traditional two-dimensional neuronal cultures fail to capture the 3D cellular organization, regional patterning, and network connectivity of the brain, while animal models, though valuable, differ from humans in critical aspects of brain development, gene expression, and disease susceptibility [1,2].

Brain organoids, also known as cerebral organoids, are three-dimensional, self-organizing neural tissues derived from human pluripotent stem cells (PSCs) that recapitulate key aspects of early human brain development. These organoids develop from embryoid bodies through a process of spontaneous neural induction and self-patterning, ultimately forming layered structures containing neural progenitors, mature neurons, and glial cells organized in a manner reminiscent of the developing cerebral cortex, ventral forebrain, or other brain regions, depending on the culture conditions [1,3]. Since the landmark publication by Lancaster and Knoblich in 2013, which demonstrated that human PSCs could form complex cerebral organoids with cortical layer organization, brain organoid technology has been rapidly adopted and refined for modeling neurodevelopmental disorders (such as microcephaly, autism spectrum disorder, and Rett syndrome), infectious diseases (including Zika virus and SARS-CoV-2), neurodegenerative diseases (such as Alzheimer's disease and Parkinson's disease), and for fundamental studies of human neurogenesis and cortical development [1,2,4].

Unlike conventional 2D neuronal cultures, brain organoids develop spontaneous electrical activity, form functional synaptic connections, and exhibit intercellular signaling networks that more closely approximate the complexity of the developing human brain. While brain organoids do not replicate the full structural and functional complexity of the adult brain (lacking vascularization, microglia, and long-range connectivity), they provide an unprecedented window into human-specific developmental processes that are inaccessible in animal models [2,5]. This article provides a comprehensive, step-by-step protocol for generating, characterizing, and maturing cortical brain organoids, with detailed technical parameters, media formulations, and quality control measures validated for reproducible results.

2. Fundamental Principles of Brain Organoid Development

Brain organoid generation exploits the intrinsic tendency of pluripotent stem cells to differentiate toward neural lineages when cultured under conditions that suppress non-neural fates. This neural bias is a well-established feature of pluripotent stem cells, which preferentially differentiate into neuroectoderm and forebrain identity in the absence of strong exogenous patterning signals [6]. The key developmental stages of brain organoid formation are:

• Embryoid Body (EB) Formation: PSCs are dissociated to single cells and allowed to re-aggregate in low-attachment plates to form homogeneous embryoid bodies. The size of the EB is critical for subsequent development, as larger EBs develop hypoxic cores that can lead to necrosis. Optimal results are achieved using 9,000–15,000 cells per EB in 96-well U-bottom low-attachment plates, which produce EBs of approximately 400–500 µm in diameter [1,3,7].
• Neural Induction: EBs are cultured in a minimal medium that does not support the growth of endoderm or mesoderm, thereby allowing the neuroectoderm to develop preferentially. Neural induction is enhanced by dual SMAD inhibition (using Noggin and SB431542) to suppress BMP and TGF-β signaling, which otherwise drive non-neural fates such as mesoderm and endoderm [8,9]. However, recent simplified protocols have shown that robust neural induction can occur even without exogenous patterning factors, as the intrinsic neural bias of PSCs is sufficient to generate forebrain organoids [7,10].
• Neuroepithelial Bud Formation: After 7–10 days of culture, the neuroectodermal tissues are embedded in Matrigel droplets to promote the formation of neuroepithelial buds that expand radially and contain fluid-filled lumens resembling the ventricular zone of the developing cortex. The Matrigel provides mechanical support and basement membrane cues that promote epithelial polarization and budding [1,3].
• Maturation and Regional Patterning: The organoids are transferred to a spinning bioreactor or placed on an orbital shaker to improve nutrient and oxygen exchange, allowing extended growth and further maturation. Over a period of 60–100 days, the organoids develop layered cortical structures with distinct ventricular zone, subventricular zone, intermediate zone, and cortical plate regions, containing diverse neuronal subtypes and, eventually, astrocytes and oligodendrocytes [1,2,5].

3. Cell Source, Preparation, and Quality Requirements

3.1 Human Pluripotent Stem Cell Lines

Both human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) have been successfully used for brain organoid generation. Commonly used lines include:

• H9 (WA09) ESC line (WiCell)
• H1 (WA01) ESC line (WiCell)
• IMR-90 iPSC line (derived from fibroblasts)
• BobC and FSPS-13B iPSC lines
• Patient-specific iPSC lines derived from individuals with neurological diseases [2,7,11]

Regardless of the specific line, PSCs should be maintained in a pluripotent state using either feeder-dependent culture (on mouse embryonic fibroblasts in knockout DMEM + 20% knockout serum replacement + FGF2) or feeder-free culture (on Matrigel or Geltrex in mTeSR1, StemFlex, or Essential 8 medium). Prior to differentiation, verify that the cells exhibit typical pluripotent morphology (compact colonies with high nuclear-to-cytoplasmic ratio and distinct borders), express pluripotency markers (OCT4, NANOG, SSEA4, TRA-1-60), and are negative for mycoplasma contamination. Karyotype analysis should be performed periodically to confirm chromosomal stability [7,10].

3.2 Single Cell Dissociation for EB Formation

1. When PSC colonies reach 60–80% confluency (typically 3–4 days after passage), aspirate the culture medium and wash the cells once with PBS without calcium and magnesium.
2. Add Accutase (STEMCELL Technologies, 07920) or TrypLE Express (Gibco, 12604013) to the cells and incubate at 37°C for 5–7 minutes. Monitor the dissociation under a microscope; the colonies should begin to lift and dissociate into single cells. Gently tap the plate to dislodge any remaining attached cells.
3. Add an equal volume of DMEM/F12 containing 10% FBS or knockout serum replacement to neutralize the enzymatic activity.
4. Transfer the cell suspension to a 15 mL conical tube and pipette gently 5–10 times to ensure complete dissociation to single cells. Pass the suspension through a 40 µm cell strainer to remove any remaining clumps.
5. Centrifuge at 300 × g for 5 minutes at room temperature.
6. Resuspend the cell pellet in EB formation medium supplemented with 10 µM Y-27632 (ROCK inhibitor, STEMCELL Technologies, 72302) to enhance single-cell survival during the initial aggregation phase [1,7,10].
7. Count the cells using a hemocytometer or an automated cell counter and adjust the concentration to the desired seeding density.

4. Media Formulation and Reagent Preparation

The media formulations for brain organoid culture are more complex than those for epithelial organoids and require careful preparation and timing. All media should be prepared using tissue culture-grade reagents and filter-sterilized before use. Growth factors and small molecules should be stored at −80°C in single-use aliquots.

4.1 Embryoid Body (EB) Formation Medium (Days 0–5)

Base: DMEM/F12 + Neurobasal Medium (1:1 mixture)

Supplements:

• 0.5% N2 supplement (Gibco, 17502048) – provides insulin, transferrin, progesterone, putrescine, and selenium
• 1% B27 supplement without retinoic acid (Gibco, 12587010) – provides essential fatty acids, antioxidants, and trace elements
• 1% GlutaMAX (Gibco, 35050061) – stabilized L-glutamine
• 1% non-essential amino acids (NEAA, Gibco, 11140050) – provides L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-glycine, L-proline, and L-serine
• 1% Penicillin/Streptomycin (Gibco, 15140122)
• 0.025% Insulin (1:100 dilution of 2.5 mg/mL stock in PBS) – supports cell survival and metabolism
• 0.035% β-mercaptoethanol (1:100 dilution of 55 mM stock in DMEM/F12) – antioxidant that reduces oxidative stress
• 10 µM Y-27632 (ROCK inhibitor) – added for the first 2 days only to prevent anoikis and promote single-cell survival [1,7,10]

4.2 Neural Induction Medium (Days 5–10)

Base: DMEM/F12 + Neurobasal Medium (1:1)

Supplements:

• 0.5% N2 supplement
• 1% B27 supplement without retinoic acid
• 1% GlutaMAX
• 1% NEAA
• 1% Penicillin/Streptomycin
• 0.025% Insulin
• 0.035% β-mercaptoethanol
• Optional: 10 µM SB431542 (Tocris Bioscience, 1614) + 100 ng/mL Noggin (PeproTech, 250-38) for dual SMAD inhibition, which enhances neural induction efficiency by suppressing TGF-β and BMP signaling [8,9]

Note: Recent simplified protocols have demonstrated that dual SMAD inhibition is not strictly required for cortical organoid formation, as the intrinsic neural bias of PSCs is sufficient to generate forebrain identity. However, for applications requiring high purity of neural tissue or for iPSC lines with poor neural induction efficiency, dual SMAD inhibition is recommended [7,10].

4.3 Neuroepithelial Expansion Medium (Days 10–18)

Base: DMEM/F12 + Neurobasal Medium (1:1)

Supplements:

• 1% B27 supplement with retinoic acid (Gibco, 17504001) – the addition of retinoic acid promotes dorsal forebrain identity
• 0.5% N2 supplement
• 1% GlutaMAX
• 1% NEAA
• 1% Penicillin/Streptomycin
• 0.025% Insulin
• 0.035% β-mercaptoethanol [1,7]

4.4 Organoid Maturation Medium (Days 18+)

Base: DMEM/F12 + Neurobasal Medium (1:1)

Supplements:

• 1% B27 supplement with retinoic acid
• 0.5% N2 supplement
• 1% GlutaMAX
• 1% NEAA
• 1% Penicillin/Streptomycin
• 0.025% Insulin
• 0.035% β-mercaptoethanol [1,3,7]

For extended culture (>60 days), some protocols recommend adding:

• BDNF (brain-derived neurotrophic factor, 20 ng/mL, PeproTech, 450-02) – promotes neuronal survival and maturation
• GDNF (glial cell line-derived neurotrophic factor, 20 ng/mL, PeproTech, 450-10) – supports dopaminergic neuron survival
• cAMP (1 µM, Sigma-Aldrich, D0260) – enhances neuronal differentiation and synaptic plasticity [2,11]

5. Step-by-Step Brain Organoid Culture Protocol

5.1 Day 0: Embryoid Body Formation

1. Count the single cells and resuspend in EB formation medium at a concentration of 60,000–100,000 cells per mL (which corresponds to 9,000–15,000 cells per 150 µL for 96-well plates, or 15,000 cells per 20 µL hanging drop).
2. For 96-well U-bottom low-attachment plates: Add 150 µL of the cell suspension per well (containing Y-27632 at 10 µM). The U-bottom shape of the wells promotes the formation of uniform, spherical EBs through gravity-driven aggregation. Alternatively, for hanging drop culture: Place 20 µL droplets containing 15,000 cells on the lid of a 10 cm petri dish (inverted over PBS to maintain humidity).
3. Centrifuge the plate at 100 × g for 3 minutes at room temperature to promote cell aggregation. This step is optional but can improve the uniformity of EB size.
4. Incubate the plate at 37°C, 5% CO2. The plate should not be disturbed for the first 48 hours to allow the cells to aggregate and form stable EBs.
5. On day 2, add 150 µL of fresh EB formation medium (without Y-27632) to each well. The Y-27632 is removed after 48 hours because prolonged ROCK inhibition can interfere with subsequent neural differentiation.
6. On day 4, perform a full medium change with fresh EB formation medium. By day 4, the EBs should be spherical, smooth, and approximately 400–500 µm in diameter. Monitor the EBs daily under a microscope to check for uniformity and absence of irregular aggregates [1,7,10].

5.2 Days 5–7: Neural Induction

1. On day 5, transfer each EB to a single well of a 24-well low-attachment plate (Corning, 3473) using a 1 mL wide-bore pipette tip or a cut P1000 pipette tip. The wide bore prevents mechanical damage to the EBs during transfer.
2. Add 1 mL of neural induction medium per well. If using dual SMAD inhibition, ensure that SB431542 (10 µM) and Noggin (100 ng/mL) are included in the medium.
3. Monitor the EBs daily under an inverted microscope. By day 6–7, healthy EBs should exhibit an optically clear, radially organized neuroectoderm on the outer edge, appearing as a smooth, bright, translucent rim. This neuroectodermal layer is the hallmark of successful neural induction and indicates that the cells are committed to a neural fate. In some EBs, the neuroectoderm may not form uniformly around the entire circumference; this is normal and the organoid can still develop successfully [1,7,10].

5.3 Days 7–10: Matrigel Embedding

1. On day 7–10, when the neuroectoderm is clearly visible as a smooth, bright rim around the EB, prepare for Matrigel embedding. This is a critical step that requires careful handling to ensure that the neuroectodermal tissue is properly oriented and supported.
2. Prepare a dimpled Parafilm sheet: Cut a sheet of Parafilm to fit inside a 10 cm petri dish. Create dimples by pressing the back of a 200 µL pipette tip into the Parafilm surface, creating small indentations approximately 3–5 mm in diameter. Sterilize the Parafilm sheet by spraying with 70% ethanol and allowing it to dry in the biosafety cabinet.
3. Place 20 µL droplets of cold Matrigel on each dimple of the Parafilm sheet.
4. Using a wide-bore pipette tip or a sterile spatula, transfer one EB per Matrigel droplet. Ensure that the neuroectodermal rim is in contact with the Matrigel, as this promotes the outgrowth of neuroepithelial buds.
5. Transfer the Parafilm sheet to a 37°C incubator and incubate for 20–30 minutes to allow the Matrigel to polymerize. The dimpled geometry helps maintain the droplet shape and prevents the EBs from flattening.
6. Using a sterile spatula, carefully transfer each polymerized Matrigel droplet containing an EB to a 6-well low-attachment plate containing 3 mL of neuroepithelial expansion medium per well.
7. Return the plate to the incubator at 37°C, 5% CO2 [1,7,10].

Note: Some simplified protocols omit the dimpled Parafilm step and instead embed the EBs directly in Matrigel droplets in the wells of low-attachment plates. While this is faster, the dimpled Parafilm method provides better control over droplet shape and promotes more uniform neuroepithelial outgrowth [7,10].

5.4 Days 10–18: Neuroepithelial Expansion

1. Perform full medium changes every 3 days using neuroepithelial expansion medium. The medium should be pre-warmed to 37°C before addition.
2. By day 10–12, neuroepithelial buds should begin to form on the surface of the organoid, visible as small protrusions extending from the Matrigel droplet. These buds represent the expansion of the neural progenitor population and are a positive sign of organoid development.
3. By day 15–18, the organoids should exhibit multiple neuroepithelial buds and may contain fluid-filled lumens resembling the ventricular zone. The organoids will increase significantly in size and density during this period, making internal structures difficult to visualize by brightfield microscopy.
4. Monitor for signs of necrosis (dark cores, disorganized tissue) and remove any organoids that appear unhealthy to prevent contamination of the culture [1,7].

5.5 Days 18+: Maturation and Long-Term Culture

1. On day 18, transfer the organoids to a spinning bioreactor (e.g., Synthecon RCCS) or place them in an orbital shaker (80–90 rpm) in a 37°C, 5% CO2 incubator. The dynamic culture improves nutrient and oxygen exchange, which is critical for the maturation of large organoids and prevents the hypoxic necrosis that commonly occurs in statically cultured organoids.
2. For the spinning bioreactor: Transfer 10–20 organoids per 10 mL vessel and rotate at approximately 20 rpm. The vessel should be filled with organoid maturation medium and the rotation speed adjusted to keep the organoids in suspension without excessive shear stress.
3. For the orbital shaker: Place the organoids in a 6 cm low-attachment dish containing 6 mL of maturation medium. Place the dish on an orbital shaker (e.g., Orbital Shaker OS-20, 80–90 rpm) inside the incubator. This method is simpler and more accessible than the spinning bioreactor and produces comparable results for most applications [1,7,10].
4. Perform medium changes every 3–4 days by carefully transferring the organoids to a fresh dish with pre-warmed maturation medium.
5. Brain organoids can be maintained for over 100 days. Mature neurons with dendritic arbors and synaptic structures appear after 60–80 days, and astrocytes begin to appear after 80–100 days. Electrophysiological activity can be detected after 60 days and becomes increasingly complex with extended culture [2,5,11].

6. Regional Specification and Specialized Brain Organoid Models

While the standard protocol described above generates organoids with predominantly dorsal forebrain (cortical) identity, directed differentiation protocols can be used to generate organoids with specific regional identities. These regionalized organoids are valuable for modeling region-specific diseases and for studying the development of specific brain structures.

6.1 Dorsal Forebrain (Cortical) Organoids

The standard protocol using dual SMAD inhibition (optional) and B27 with retinoic acid promotes dorsal forebrain identity. The intrinsic neural bias of PSCs, combined with the absence of ventralizing signals (such as SHH), is sufficient to generate cortical organoids containing neural progenitors (PAX6+, SOX2+), deep layer neurons (CTIP2+, TBR1+), and upper layer neurons (SATB2+, CUX1+). The organoids develop a layered structure reminiscent of the cortical plate, with progenitors located in the outer regions (ventricular zone-like) and neurons in the inner regions (cortical plate-like) [1,7,10].

6.2 Ventral Forebrain Organoids

Ventral forebrain organoids contain GABAergic interneurons and are generated by adding ventralizing morphogens during the neural induction phase. Add recombinant sonic hedgehog (SHH, 100–500 ng/mL, R&D Systems, 1845-SH) or the small molecule smoothened agonist SAG (0.5–1 µM, Calbiochem, 566660) to the neural induction medium from day 5–10. The ventralized organoids will express markers of the medial ganglionic eminence (MGE), including NKX2-1, LHX6, and SST (somatostatin), and will generate parvalbumin-positive and somatostatin-positive interneurons. These interneurons can migrate and integrate when co-cultured with cortical organoids, providing a model for studying interneuron migration and cortical circuit assembly [2,12].

6.3 Midbrain Organoids

Midbrain organoids containing dopaminergic neurons are generated by adding FGF8 (100 ng/mL, PeproTech, 100-25) and SHH (200 ng/mL) during days 5–10 of neural induction, followed by Wnt1 (25 ng/mL, R&D Systems, 1368-WN) and BDNF (20 ng/mL) during the expansion phase. These organoids develop tyrosine hydroxylase-positive (TH+) dopaminergic neurons and can be used to model Parkinson's disease and to screen for dopaminergic neuroprotective agents [13].

6.4 Cerebellar Organoids

Cerebellar organoids are generated by adding FGF2 (20 ng/mL), insulin (4 µg/mL), and SAG (1 µM) during the neural induction phase, followed by BMP4 (10 ng/mL) during the expansion phase. These organoids develop Purkinje cells and granule cells and can be used to model cerebellar developmental disorders [14].

6.5 Hippocampal Organoids

Hippocampal organoids are generated by adding Wnt3a (25 ng/mL) and BDNF (20 ng/mL) during the expansion phase, which promotes the development of CA1-like and CA3-like pyramidal neurons and dentate gyrus granule cells. These organoids can be used to model hippocampal neurogenesis and memory-related disorders [15].

7. Quality Control, Validation, and Functional Characterization

7.1 Morphological Assessment by Brightfield and Phase-Contrast Microscopy

Healthy brain organoids should exhibit the following morphological features at different stages:

• Day 5–7: Spherical EBs with smooth, bright neuroectodermal rims. The neuroectoderm should appear as an optically clear, radially organized layer on the outer surface of the EB. The inner mass of the EB may appear darker and less organized.
• Day 10–15: Neuroepithelial buds begin to form on the surface of the organoid, visible as small protrusions extending from the Matrigel droplet. The buds may appear as continuous sheets or rounded compact structures.
• Day 18–30: Multiple neuroepithelial buds grow and expand, causing the organoid to increase significantly in size and density. The organoids become opaque and difficult to visualize by brightfield microscopy.
• Day 60+: Mature organoids are large (3–5 mm diameter), dense, and opaque. They may develop convoluted surfaces and internal structures that are not visible by brightfield microscopy. Sectioning is required for detailed morphological analysis [1,7,10].

Common pitfalls and their morphological correlates:

• Failure to form neuroectoderm by day 7: The EBs remain dark and irregular, with no clear outer rim. This may indicate insufficient neural induction or poor cell quality.
• Necrosis in the organoid core: A dark, disorganized region in the center of the organoid, often surrounded by healthy tissue. This is caused by inadequate oxygen and nutrient diffusion and can be reduced by dynamic culture (shaking or spinning bioreactor).
• Excessive non-neural tissue: The presence of cystic structures, pigmented cells, or other non-neural tissue types indicates incomplete neural induction. This is more common in iPSC lines with poor neural bias and can be corrected by dual SMAD inhibition [7,10].

7.2 Immunofluorescence Characterization

Immunofluorescence staining of cryosectioned brain organoids is essential for validating the cellular composition, regional identity, and developmental stage. The following protocol is adapted for brain organoids:

1. Fix organoids in 4% paraformaldehyde (PFA) in PBS for 45 minutes at room temperature. For large organoids (>3 mm), extend the fixation time to 60 minutes or perform perfusion fixation by injecting PFA into the organoid using a fine needle.
2. Wash the organoids three times with PBS (15 minutes each wash).
3. Incubate the organoids in 30% sucrose in PBS overnight at 4°C for cryoprotection. The organoids will sink to the bottom of the tube when fully infiltrated.
4. Embed the organoids in optimal cutting temperature (OCT) compound in cryomolds. Freeze on dry ice or in a −80°C freezer.
5. Cryosection the organoids at 10–20 µm using a cryostat. Collect sections on charged glass slides (e.g., SuperFrost Plus).
6. Permeabilize the sections with 0.3% Triton X-100 in PBS for 15 minutes at room temperature.
7. Block with 2% normal goat serum + 2% bovine serum albumin in PBS for 1 hour at room temperature.
8. Incubate with primary antibodies diluted in blocking buffer overnight at 4°C.
9. Wash three times with PBS (5 minutes each).
10. Incubate with fluorophore-conjugated secondary antibodies (e.g., Alexa Fluor 488, 555, 647) for 1 hour at room temperature.
11. Counterstain with DAPI (1 µg/mL) for 5 minutes.
12. Mount with antifade mounting medium and image with a fluorescence microscope or confocal microscope [1,7,11].

Key immunofluorescence markers for brain organoid characterization:

• Pluripotency (before differentiation): OCT4, NANOG, SSEA4, TRA-1-60
• Neural progenitors (ventricular zone-like): SOX2, PAX6, NESTIN, FOXG1
• Early neurons: βIII-tubulin (TUBB3), MAP2, DCX (doublecortin)
• Deep cortical layer neurons: TBR1 (layer 6), CTIP2 (layer 5), BCL11B
• Upper cortical layer neurons: SATB2 (layers 2–4), CUX1, BRN2
• GABAergic interneurons: GAD67, GABA, SST (somatostatin), PV (parvalbumin), CALB2 (calretinin)
• Astrocytes: GFAP, S100β, ALDH1L1 (appear after 60–80 days)
• Oligodendrocytes: O4, MBP (myelin basic protein), appear after 100+ days in some protocols
• Synaptic markers: Synaptophysin, PSD95, VGLUT1, VGAT
• Proliferation: Ki67, PHH3 (phospho-histone H3), EdU (thymidine analog) [2,5,11]

7.3 Electrophysiological Validation

Electrophysiological recordings are the gold standard for validating the functional maturity of neurons in brain organoids. The following methods can be used:

• Patch-Clamp Recordings: Whole-cell patch-clamp recordings can be performed on acute slices of brain organoids (200–300 µm thick) or on dissociated organoid-derived neurons plated on coverslips. Mature neurons should exhibit:
  • Resting membrane potential of approximately −60 to −70 mV
  • Action potential firing in response to depolarizing current injections
  • Spontaneous excitatory postsynaptic currents (sEPSCs) indicating functional synaptic connectivity
  • Voltage-gated sodium and potassium currents [2,5,11]
• Calcium Imaging: Spontaneous network activity can be visualized using calcium indicator dyes (e.g., Fluo-4 AM, Fura-2 AM) or by generating GCaMP-expressing organoids using lentiviral transduction or genetic engineering. Calcium imaging reveals synchronized calcium transients that represent network-level spontaneous activity, which becomes increasingly complex with extended culture duration. By day 60–100, organoids exhibit spontaneous network bursts resembling cortical network activity [2,5,11].
• Multi-Electrode Array (MEA) Recordings: Organoids can be plated on MEA dishes containing embedded microelectrodes, which allow non-invasive recording of extracellular field potentials. MEA recordings can detect spontaneous firing, network oscillations, and responses to pharmacological manipulations (e.g., glutamate receptor agonists, GABA receptor modulators) [2,11].

7.4 Single-Cell RNA Sequencing (scRNA-seq)

Single-cell transcriptomic analysis is increasingly used to validate the cellular diversity and transcriptomic similarity of brain organoids to the developing human brain. scRNA-seq of brain organoids typically reveals the presence of:

• Radial glia (expressing PAX6, SOX2, VIM, HES1)
• Intermediate progenitors (expressing TBR2, EOMES)
• Excitatory neurons (expressing NEUROD2, BCL11B, SATB2, TBR1)
• Inhibitory neurons (expressing GAD1, GAD2, DLX2, LHX6)
• Astrocytes (expressing GFAP, AQP4, S100B, ALDH1L1)
• Oligodendrocyte precursor cells (expressing PDGFRA, OLIG2)
• Microglia-like cells (rare in standard protocols; require microglia inclusion or co-culture) [5,11]

Comparative analyses between brain organoids and the developing human brain (e.g., using datasets from the BrainSpan Atlas) have shown significant transcriptomic similarity, particularly for early to mid-gestational stages. However, organoids also exhibit divergent gene expression patterns related to stress responses, metabolic differences, and the absence of vascular and microglial signals [5,11].

8. Troubleshooting Common Issues in Brain Organoid Culture

Issue: EBs fail to form uniform, spherical aggregates

Potential Causes and Solutions:

• Cell quality is poor: Ensure that PSCs are in a healthy, undifferentiated state before dissociation. Cells with high passage numbers or signs of differentiation may form irregular aggregates.
• Dissociation is incomplete: Ensure that cells are fully dissociated to single cells before plating. Pass the suspension through a 40 µm strainer to remove clumps.
• Plate is disturbed during the first 48 hours: Do not move or disturb the plate during the initial aggregation phase. Place the plate in a stable location in the incubator.
• Y-27632 is inactive or omitted: Verify the Y-27632 stock concentration and activity. Include Y-27632 at 10 µM for the first 48 hours to enhance single-cell survival [7,10].

Issue: Neuroectoderm does not form by day 7

Potential Causes and Solutions:

• Dual SMAD inhibition is insufficient: If using dual SMAD inhibition, verify that SB431542 (10 µM) and Noggin (100 ng/mL) are present and active. Increase the concentration if necessary.
• Medium composition is incorrect: Verify that the B27 supplement does not contain retinoic acid during the neural induction phase (days 5–10). Retinoic acid promotes dorsal forebrain identity but can interfere with early neural induction if added too early.
• The EB size is too large or too small: EBs that are too large (>600 µm) may develop hypoxic cores and fail to form organized neuroectoderm. EBs that are too small (<300 µm) may not generate sufficient cell-cell signaling for neural induction. Optimize the seeding density to achieve 400–500 µm EBs [7,10].
• iPSC line has poor neural induction efficiency: Some iPSC lines exhibit poor neural induction. Try adding dual SMAD inhibition, increasing the seeding density, or using a different iPSC line.

Issue: Organoids undergo necrosis in the core

Potential Causes and Solutions:

• EB size is too large: Reduce the seeding density to 9,000–10,000 cells per EB.
• Static culture does not provide adequate oxygenation: Transfer the organoids to a spinning bioreactor or orbital shaker by day 18 at the latest. Earlier transfer (day 10–15) may be beneficial for some lines.
• Medium changes are insufficient: Increase the frequency of medium changes to every 2–3 days. Ensure that the medium is fully equilibrated with CO2 before addition.
• Organoids are too dense: Reduce the number of organoids per dish or bioreactor vessel to improve nutrient access [1,7].

Issue: Excessive non-neural tissue (mesoderm, endoderm, or unidentified cystic structures)

Potential Causes and Solutions:

• Dual SMAD inhibition was omitted or insufficient: Add SB431542 (10 µM) and Noggin (100 ng/mL) during days 5–10 to suppress non-neural fates.
• Noggin is inactive: Prepare fresh Noggin stock. Verify that the Noggin is present at the correct concentration.
• The PSC line has poor neural bias: Some lines, particularly those derived from certain somatic cell types or reprogrammed with certain factor combinations, may have reduced neural induction efficiency. Consider using a different iPSC line or increasing the dual SMAD inhibition.
• The culture medium contains contaminants: Check for bacterial or fungal contamination. Ensure that all reagents are of tissue culture grade [7,10].

9. Conclusion and Practical Recommendations

Brain organoid culture provides an unprecedented platform for studying human neurodevelopment, modeling neurological diseases, and screening neuroactive drugs in a physiologically relevant 3D system. The generation of cortical organoids with layered structures and functional neural networks has opened new avenues for understanding the cellular and molecular mechanisms underlying human brain development and disease. The key factors for successful brain organoid culture include: (1) the use of high-quality, pluripotent stem cells with verified identity and normal karyotype; (2) careful control of EB size and uniformity; (3) timely neural induction and Matrigel embedding; (4) transition to dynamic culture (spinning bioreactor or orbital shaker) to prevent necrosis and promote maturation; and (5) rigorous validation using immunofluorescence, electrophysiology, and transcriptomics.

As the field continues to evolve, several important advances are on the horizon: the incorporation of microglia and other immune cells to model neuroinflammation; the vascularization of organoids to improve oxygenation and nutrient delivery; the development of multi-region assembloids that model inter-regional connectivity; and the integration of brain organoids with microelectrode arrays and brain-computer interfaces for functional studies. GBiowit is committed to supporting brain organoid research through our comprehensive product portfolio, which includes defined neural media formulations, Matrigel and synthetic matrix alternatives, brain organoid kits with validated protocols, and specialized services for brain organoid generation, characterization, and drug screening.